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ABSTRACT 
 
 
 This project focuses on SARS coronavirus infection.  Immunofluorescence 
microscopy was used to locate several factors that could help in investigating SARS 
pathology.  The locations of two cytokines were investigated in relation to SARS CoV 
infected cells.  Infected cells were also stained to determine their cell type.  SARS CoV 
infected cells did not stain positive for macrophage or epithelial cell markers.  SARS 
CoV infected cells were also not producing TGF-β or TNF-α, two prominent cytokines 
involved with inflammation.  These results will be used to design in vitro experiments to 
further examine SARS CoV infection.  
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BACKGROUND 
  
 Late in the year 2002, Southern China began to see the emergence of an unknown 
acute respiratory syndrome.  By February 2003, there were 305 confirmed cases and 5 
deaths resulting from this unknown syndrome.  The cases had spread through households 
and through healthcare workers.  Over the next month, the disease began to spread 
rapidly throughout Southeast Asia.  The unknown disease was termed “severe acute 
respiratory syndrome”, or as it is more commonly known now, “SARS”.  The outbreak 
spread to several other countries through international travel, Canada being the closest to 
the United States, but the spread was limited.  The World Health Organization and Center 
for Disease Control began researching, and this new disease became of high interest to 
many scientists around the globe.  This MQP focuses on the pathology of SARS, 
especially the role of cytokines.  The data obtained will eventually be used to develop 
further in vitro experiments with SARS CoV, with the overall goal of determining the 
pathophysiology underlying SARS CoV infection.  With this knowledge it may be 
possible to rationally develop a vaccine against SARS CoV, preventing future outbreaks 
like that of 2003. 
 
SARS Coronavirus 
 Shortly after the outbreak of SARS, the World Health Organization (WHO) setup 
a global association of laboratories to concentrate on identifying the causative agent for 
SARS.  Early after the outbreak, several sources were cited for the possible reasons for 
SARS.  Some scientists theorized that the SARS outbreak was related to the recent 
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outbreak of an avian influenza.  This was ruled out due to lack of data, and the Chinese 
reported Chlamydia-like organisms in fatal cases of SARS.  This was eventually rejected, 
as results could not be duplicated outside of China.  At this point the WHO began its 
network of laboratories to search for the cause.  The labs frequently met through 
telephone conferences and virtual communication.  In late March of 2003, labs in the 
United States, China and Germany all had found evidence of a novel coronavirus in the 
blood of patients with SARS.  In April, the WHO confirmed this virus as the cause for 
the disease.   
 
SARS CoV Identification 
 To identify the cause of this disease, several tests were run on the blood of an 
index patient and two of his close contacts.  As is standard practice in identifying 
unknown pathogens, the blood and respiratory specimens were tested by polymerase 
chain reaction (PCR) with specific primers for several known human pathogens.  Some of 
these included human cytomegalovirus, adenovirus, parainfluenza virus of several strains, 
Chlamydia pneumoniae and several coronavirus strains.  General primers for many other 
common viruses were also used (Drosten, et al, 2003).  A random reverse transcriptase 
PCR (RT-PCR) reaction was run with extracted RNA as well.  The results came back 
negative on all pathogens tested, with a few minor exceptions that were dismissed as 
possible causes.  However, a cytopathic effect was seen on Vero-E6 cells incubated with 
sputum from the index patient.  After one passage of these cells, nucleic acids were 
isolated from the supernatant.  About 20 different distinct DNA fragments were 
amplified.  Most of these turned out to match monkey chromosome sequences, as the 
Vero cells are obtained from monkeys.  However three fragments did not match any 
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sequence in the database.  The Basic Local Alignment Search Tool (BLAST) was used 
with the translated sequences of unknown origin.  The sequence showed homology to the 
coronavirus amino acid sequences leading scientists to see that a novel coronavirus had 
been isolated (Drosten, et al, 2003).  Two of the fragments were 300 nucleotides in 
length, and the third was 90 nucleotides (Figure 1).         
 
Figure 1:  Nucleotide and Amino Acid Sequence Alignment of the Original SARS CoV Fragments 
with Other Coronaviruses.  The top part of the figure shows the nucleotide alignment of fragment BNI-1 
with other known coronaviruses.  The bottom part shows the amino acid alignment of the same.  The 
nucleotide sequence was translated into one-letter amino acid code.  A dot indicates identical sequence to 
the reference sequence.  The primers for RT-PCR (brown) and real-time PCR (blue) are shown and point in 
the direction of elongation (Drosten, et al, 2003). 
 
 
Coronaviridae 
 Coronaviruses belong to the order Nidovirales and the family Coronaviridae.  
They are large, single positive-strand RNA viruses.  They range in diameter from about 
60-220 nanometers.  Coronaviruses have the largest genome of any RNA virus, ranging 
from 27-32 kilobases.  Before the identification of SARS coronavirus (CoV), there were 
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three groups of coronaviruses.  Two of these infected mammals and caused anywhere 
from the common cold to a rare fatal pneumonia in humans.  The third group infected 
birds and was of no harm to humans.  However, when SARS CoV was discovered, a 
fourth group of coronaviruses needed to be added.  Upon analysis of the newly 
discovered SARS CoV, it was seen that genetically, the new SARS virus was not related 
to the previous human coronaviruses, but rather more closely related to animal strains 
that infected Chinese civet cats.  Civet cats are commonly eaten in Southern China, the 
proposed origin of the SARS outbreak.  It is believed that the virus may have been passed 
from these cats into the human population, although it has not been scientifically proven.   
 
SARS-CoV Genome 
 Once this coronavirus was officially declared as the cause of SARS, research 
began to sequence the genome of this new virus.  A Canadian group was the first to 
sequence the SARS CoV (Marra, et al, 2003), followed two days later by the Center for 
Disease Control in the United States (Rota, et al, 2003).  It was found that the SARS-CoV 
genome was comprised of 29,727 bases of polyadenylated RNA.  The organization of the 
genome (Figure 2) was characteristic of most coronaviruses, having the following normal 
gene order: 5’-replicase(rep), spike(S), envelope(E), membrane(M), nucleocapsid(N)-3’ 
(Rota, et al, 2003).  The rep gene comprises two-thirds of the SARS CoV genome.  There 
are four open reading frames (ORFs) downstream of the rep gene that encode the 4 
structural proteins, S, E, M and N.   
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Figure 2:  Genome Structure of SARS CoV – This figure shows the organization of the SARS CoV 
genome.  The fragments labeled X represent nonstructural proteins of unknown function (Rota, et al, 2003). 
 
  
 Through more detailed analysis, the SARS CoV genome was determined to be  
phylogenetically different from the other known coronaviruses.  The five major proteins 
in the genome were compared phylogenetically to the other known proteins for the 
known coronaviruses.  In all cases, the SARS CoV separated into distinct, well-defined 
branch on the tree.  Bootstrap analyses were preformed and values above 90% were 
recorded (Rota, et al, 2003).  It was seen that there was greater conservation of the 
enzymatic proteins like polymerase and helicase, and less conservation of the structural 
proteins.  This information shows that SARS CoV forms its own distinct group within the 
genus Coronavirus.  It was also seen that there was very little recombination in the SARS 
CoV and that it also wasn’t a mutant of the previously known strains. 
 
SARS CoV Structure and Function 
 The SARS CoV is similar in structure to most other coronaviruses (Figure 3).  
The essential structural proteins, S, E, M, and N all exist and are basically similar.  There 
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are, however, some differences that make the SARS CoV different.  These differences are 
the focal point of research in finding a cure, and even a vaccine for the disease. 
 The replicase gene of SARS CoV makes up two-thirds of the entire SARS CoV 
genome.  Two ORFs exist that produce two major polyproteins that undergo proteolytic 
processing to yield the enzymes and proteins needed for viral replication.  One of these 
polyproteins is a chymotrypsin-like protease that is involved in the proteolytic cleavage 
to yield the resulting replication enzymes.  This protease has become a target for possible 
anti-SARS CoV agents.  If this protein is altered or inhibited, the viral replication cannot 
commence, halting infection. 
 The nucleocapsid protein of the SARS CoV is another protein that shares very 
little with other known coronaviruses, in the area of 20-30% sequence homology.  In 
other coronaviruses, the N protein is involved with transcription of the viral genome and 
packaging of the viral RNA, but these roles have not been defined in the SARS CoV.  
The N protein also elicits a humoral response in infected patients.   
                        
                               
Figure 3: EM Micrograph of the SARS 
Coronavirus.  This electron micrograph shows 
the coronavirus particle, including the S protein 
forming the halo, or “crown” on the exterior.  
Picture from The Big Picture Book of Viruses,  
http://www.virology.net/Big_Virology/BVRNAcorona.html. 
 
   
 
 
 The spike protein of the SARS CoV is the other protein that shows distinct 
differences from other coronaviruses.  The S protein is divided in two subunits, S1 and 
S2.  S1 is responsible for cellular receptor recognition, and the S2 subunit is responsible 
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for cellular fusion, or virulence.  The S protein is very little conserved compared the other 
coronaviruses, about 20-27%, as seen in Figure 4 (Rota, et al, 2003).  Due to this fact, the 
comparison of primary amino acid sequences gives very little information on the receptor 
binding specificity or the antigenic properties of SARS CoV.  However, the fact that the 
SARS CoV S protein is known to be the primary protein responsible for viral entry, 
experiments were conducted to determine possible cellular receptors.  Analysis of protein 
isolated by immunoprecipitation with SARS CoV infected Vero E6 cells showed 
sequence analysis with human angiotensin-converting enzyme 2, or ACE2 (Li, et al, 
2003).  This protein’s cellular localization and distribution made it an appropriate 
receptor for the SARS CoV. 
   
  
Clinical SARS 
 SARS is very difficult to identify, especially in the winter months due to the rise 
in flu and common cold cases.  Some of the symptoms include fever, chills, headache, 
malaise, cough and other fairly common symptoms.  However, as the SARS CoV 
infection progresses, the symptoms worsen and intensify, leading to leukopenia, or low 
Figure 4: Conserved 
Regions of the SARS-
CoV S Protein.  This 
figure shows the 
regions of the S 
protein of SARS-CoV 
compared with other 
known coronaviruses.  
It can be seen that the 
membrane spanning 
region is fairly similar, 
but the cytoplasmic 
regions differ greatly. 
Rota et al, 2003. 
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white blood cell count, T-Lymphopenia, or low T-cell count and even acute respiratory 
distress, where the lungs become inflamed and fluid collects in the alveoli.   
 Several factors occur in the pathology of SARS.  One large event is exudation of 
protein containing fluid in the lungs.  The lungs become “leaky” with an inflammatory 
liquid that threatens pulmonary gas exchange.  The pathology is that of typical diffuse 
alveolar damage (DAD).  There are three main phases of DAD:  the exudative phase, 
proliferative phase and the fibrotic phase.  The exudative phase begins 4 to 7 days after 
onset, leading the lungs to become heavy and the pulmonary capillaries become 
congested.  The proliferative phase, beginning 1-3 weeks post onset, shows organized 
inflammation and early fibrosis.  Lastly, the fibrotic phase, 3-4 weeks after onset, shows 
complete lung remodeling by sparsely cellular collagenous tissue.    
 Several methods are used to determine if the SARS CoV is the cause of infection.  
One is the use of RT-PCR to detect viral mRNA in the nasal aspirate of patients.  This 
procedure is effective, although it requires some time.  The easier method of 
determination is serological assays.  Recently, antibodies have been characterized against 
the S and N proteins of the SARS CoV (Tan, et al, 2004).  Some data from this paper 
show that all convalescent-phase sera showed reactivity with the S protein antibody.  
However, sera from the acute phase (2-9 days post infection) showed no reactivity, 
suggesting that the N protein antibodies are present earlier in the humoral response (Tan, 
et al, 2004).    It has been seen that DNA immunization with N protein from a porcine 
coronavirus induced immunity by T-cell activation and memory (Liu, et al, 2001).  This 
data shows that not only can these antibodies be used to detect SARS CoV infection 
earliest, but can also be a method of building a strong, early immune response. 
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The Immune System 
 To better understand the way SARS CoV affects the human body, one must 
understand the human immune system.  This system is very complex with the main goal 
of destroying invading pathogens to prevent illness.  There are two systems involved in 
response to an invading pathogen:  innate immunity and adaptive immunity.   
 
Innate Immunity 
 Innate immunity is what every human is born with as a first line of defense for 
preventing illness.  On the large scale there are several barriers in place to prevent entry 
of foreign pathogens.  First and foremost, the skin cannot be penetrated unless it has an 
opening, such as a nick, cut or scratch.  Secondly, the natural actions of sneezes and 
coughs are methods of expelling living and non-living things from the respiratory system.  
Mucus is another line of defense, catching bacteria and pathogens in the nasal and 
respiratory tracts.  Lastly, many of the body’s secretions and fluids are acidic and prove 
to help destroy bacteria that are not welcome on the skin and in certain areas in our body.  
Sweat, tears, saliva and stomach acid are a few fluids that help protect from invading 
bacteria and pathogens.   
 On a smaller scale, there are many cells inside our body whose sole purpose is to 
destroy foreign material.  Every cell in our body has a marker celled the major 
histocompatibility complex.  This is the body’s way of determining self and non-self.  
Any cell that does not display this marker is considered non-self and attacked.  The innate 
immune system has no specific memory and does not process foreign antigens in what is 
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a rapid early response to infection.  Cells called phagocytes are responsible for adhering, 
engulfing and ingesting foreign bodies.  Monocytes, or macrophages, flow through our 
blood stream and can even exit the blood to move towards an infection site to destroy 
invading bacteria.  Other cells called natural killer cells, or NK cells, flow through the 
blood and lymph systems destroying cancerous and viral containing cells.  Neutrophils 
are short-living white blood cells that are usually the first to arrive at an infection site.   
 
Adaptive Immunity 
 Adaptive immunity is a complex system with a main goal of mounting a specific 
response against specific antigens.  The two major cells involved with adaptive immunity 
are the T-cell and the B-cell.  Both these lymphocytes flow through the blood and lymph 
systems.  They perform two types of immunity:  cell-mediated and humoral immunity. 
 Cell-mediated immunity involves macrophages and other antigen-presenting cells 
like dendritic cells and even B cells.  The macrophage will engulf foreign antigen through 
endocytosis.  The antigen will then be inactivated through enzymatic processing.  
Enzymes will then move a small part of the antigen to the macrophage surface, 
presenting it to the T-cells.  This sensitizes the T-cell to recognize these antigens and 
mount a memory response.  Other cells called cytotoxic or killer T-cells release 
lymphotoxins that cause cell lysis.  Helper T-cells mediate this process by directing the 
immune response.   
 The humoral response is a bit more complicated.  When an immature B-cell is 
presented an antigen, it becomes sensitized and undergoes clonal selection.  It divides and 
most of them become plasma cells.  After an initial lag, these cells begin to produce 
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antibodies at a rate of up to 200 per second for 4-5 days.  Antibodies are soluble proteins 
that inactivate antigens by several methods:  attaching to antigens and causing cell lysis, 
blocking antigen-binding sites, causing aggregation and precipitation.  There are many 
forms of antibodies and their exact methods have been detailed, although they are not a 
major point of this paper.   
 B-cells that do not become antibody-releasing cells can become long-lived 
memory cells.  These cells, along with the memory T-cells form the main point of the 
adaptive immunity:  immune memory.  If by chance the same antigen is found in the 
body after an initial infection, the second response will be much faster and much stronger 
than the initial response.  This is a quality unique to the adaptive immune system.   
This system provides the basis for prophylactic vaccination.  The point of 
vaccines is to introduce an inactivated, attenuated antigen to the body.  By doing this, the 
body will mount an immune response to this antigen.  Therefore, when the true infectious 
antigen enters the body, it will elicit a much quicker immune response and the infectious 
agent will be destroyed quickly.  In theory, this concept seems like a “cure-all”, but in 
reality, the formation of an effective vaccine proves to be a difficult task.   
 
Cytokines 
 The cellular components of the immune response are not the sole messengers 
during infection.  Small, secreted proteins called cytokines are used as messengers during 
the reaction to an infection.  These proteins are responsible for the regulation of 
immunity, inflammation and hematopoiesis.  Cytokines act by binding to specific 
membrane receptors and, with the help of secondary messengers like tyrosine kinases, 
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alter the gene expression of the target cell.  Some responses to cytokines include an 
increase or decrease in certain protein production, proliferation of the cell or secretion of 
effector molecules.  There are many types of cytokines, each triggering different 
responses from the target cells.  However, more than one cytokine can elicit the same 
response from a cell and also the same single cytokine can exhibit pleotropism, meaning 
it can have many functions.  They also often work in a cascade, with one cytokine 
triggering the response of more cytokines and so on.   
 There are many different types of cytokines.  The interleukin class of cytokines is 
made by leukocytes and act on other leukocytes.  The interferon class, more specifically 
IFNα and IFNβ act on viral infected cells, halting viral replication.  Two cytokines are the 
principal focus in this experiment.  They are the transforming growth factor beta (TGF- 
β) and tumor necrosis factor alpha (TNF- α). 
 
Transforming Growth Factor Beta 
 Transforming growth factor-beta, or TGF-β, is a gene superfamily of structurally 
and functionally related proteins.  There are three different isoforms, the effect of each 
dependent on the conditions of the target cell and other growth factors present.  It’s 
functions include signaling cellular proliferation in vitro, but is also generally considered 
as an inhibitor of proliferation and promoter of differentiation (Choi et al, 1993).  It has 
also been shown to block or initiate cellular differentiation and migration, depending on 
the surrounding conditions and the conditions of the target cell.  As one can see, the roles 
of TGF-β are very broad and are all dependent on surrounding conditions.  
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 One function of TGF-β is the role it plays in vascular remodeling.  TGF-β1, 
which is the predominant isoform, can inhibit the activity of other angiogenic factors in 
endothelial proliferation, and can stimulate the production of extracellular matrix proteins 
and proteinase inhibitors (Pepper, 1997).  However, the cytokine shows a biphasic effect 
on angiogenesis.  When TFG-β concentration is low, there is an increase in the vascular 
invasion of cultured endothelial cells that were stimulated by other angiogenic factors.  
When the concentration of TGF-β is high, there is a decrease in such invasion (Pepper, et 
al, 1993).   
 The restoration of an epithelial layer after damage is important to maintain a 
healthy respiratory tract.  TGF-β1 and TGF-β2 have been studied in relation to their role 
in this repair.  It has been seen that both isoforms were converted to their active forms 2 
hours after wounding, and TGF-β1 speeds up the process of epithelial repair (Howat, et 
al, 2002).   
 Human carcinomas also have ties to TGF-β.  Cancer cells lack the signal to divide 
or die when they become too large.  The growth is uninhibited.  TGF-β is one of the 
cytokines that signal a cell to stop growing or to lyse.  This is why most carcinomas are 
characterized by their lack of normal growth-inhibiting and apoptotic responses to TGF-β 
(Reiss, 1997).  The roles of TGF-β are many, and as the molecular and cell biology is 
relatively well known, the signaling pathways are just beginning to be discovered.  
  
Tumor Necrosis Factor Alpha 
 Tumor necrosis factor alpha, or TNF-α, is also a cytokine that is produced in a 
variety of cells, but especially by macrophages.  Like TGF-β, this cytokine has many 
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functions in the body, most not fully understood yet.  TNF-α is released by stimuli such 
as exposure to bacterial toxins, viruses such as HIV and influenza, fungi, parasites and 
other cytokines.  TNF-α also appears to possess a self-regulating ability as well.  The 
scope of its functions is too broad to cover completely, so instead a few main functions 
will be discussed.   
Strictly by seeing it’s name alone, one can realize that this cytokine has a tumor 
suppressing quality.  In fact, it was first isolated in 1975 during an attempt to identify the 
cause for tumor necrosis in the sarcoma Meth A (Carswell, et al, 1975).  However, in 
some conditions, TNF-α been known to promote growth in certain tumor cells.  High 
levels of TNF-α have been linked to increased mortality in tumor patients in some 
circumstances (Rink and Kirchner, 1996).  There are also other functions of this cytokine 
that do not involve tumors or cancer.   
 One negative aspect of TNF-α is its involvement in septic shock syndrome.  
Sepsis is the presence of bacteria or other invading organism and the toxins that are 
involved with the infection.  It was once believed that solely the invading organisms and 
their toxins caused the syndrome.  Now it is seen that the cause of the syndrome may be 
all due to the overproduction of cytokines, primarily TNF-α.  This is because TNF-α is 
acutely overproduced during extreme sepsis and administration of TNF-α itself, 
regardless of sepsis, causes shock and tissue injury (Tracey and Cerami, 1994).  This and 
other data show that septic shock can be associated to TNF-α and not sepsis.  When TNF-
α is removed from the system, septic shock does not ensue even with the existence of 
bacteria in the bloodstream (Tracey, et al, 1987). 
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 One positive affect of TNF-α is its role in the inflammation response.  It has been 
shown that TNF-α activates leukocytes, enhances the adherence of neutrophils and 
monocytes to the endothelium, induces fibroblast proliferation and triggers the release of 
other pro-inflammatory cytokines.  These beneficial functions contribute to the 
localization of infection and the increase of tissue remodeling.  It can be presumed that 
these features, not the negative ones that have been mentioned, led to the conservation of 
the TNF gene through evolution (Tracey and Cerami, 1994). 
   
TGF-β and TNF-α in viral replication 
TGF-β is also known to affect viral replication, although it has never been tested 
on SARS CoV specifically.  As an anti-inflammatory cytokine, TGF-β acts by inhibiting 
inflammation of tissue, and therefore would help the virus by not clearing it from the 
system.  This would be a positive affect on viral replication.  However, a study was 
conducted on tuberculosis-induced HIV infection and it was shown that in vitro, TB 
induced HIV showed high levels of pro-inflammatory cytokines like interleukins 2, 6 and 
8 (Goletti, et al, 1997).  It was then found that the addition of anti-inflammatory 
cytokines like IL-10 and TGF-β inhibited TB induced HIV replication.  In this model, 
TGF-β inhibited the viral replication by decreasing cellular proliferation, and by 
decreasing the endogenous pro-inflammatory cytokines (Goletti, et al, 1997).  This is 
proof that the effect of cytokines on viral replication is dependent on circumstances 
regarding the specific virus.       
TNF-α affects viral replication in different ways.  This cytokine has several 
affects on viral replication and could be looked at as a “dual-edge sword”.  This means 
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that TNF-α can affect viral replication in a positive or negative way, depending on the 
circumstances during replication.  As a pro-inflammatory cytokine, TNF-α promotes 
inflammation of tissue and promotes the clearance of virus (Haagmans, et al, 1994).  
However, it has been shown that TNF-α can also promote viral replication of rat CMV 
under certain conditions (Haagmans, et al, 1994).  This shows the pleotropism of TNF-α 
and its affects on viral replication. 
 
TGF-β and TNF-α in Acute Lung Injury 
 Acute lung injury, or ALI, is a devastating disorder with a mortality rate of 30-
40%.  There is no known cure.  The disorder is characterized by flooding of the alveolar 
spaces with a protein-rich exudate that impair the pulmonary gas exchange.  This 
pathology is the beginning of diffuse alveolar damage, as mentioned before.  ALI can 
follow many complications like sepsis, toxic inhalation and even SARS.   
 TGF-β has been shown to play a critical role in the resolution of tissue injury in 
many organs, including the lungs.  It has been most evaluated in the late phases of ALI 
where it plays a major role in pulmonary tissue fibrosis.  However a study showed that 
TGF-β may be active earlier, even up to 2 days after the induction of the injury.  It was 
reasoned that TGF-β may be active much earlier and play a larger role in the 
development of the pulmonary edema that distinguishes the disorder (Pittet, et al, 2001).  
Results showed that TGF-β was activated by an integrin (αVβ6) in the lungs and skin.  
Transgenic mice that lacked this integrin were protected from pulmonary edema in a 
model of ALI.  The results from this study show that the integrin-mediated activation of 
TGF-β is crucial in the formation of the pulmonary edema in ALI.  Blocking the TGF-β 
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or its activation could protect from the formation of the edema and overall the induction 
of ALI (Pittet, et al, 2001).  Though TGF-β is generally considered to be critical in the 
resolution phase of lung tissue injury, inhibiting inflammation and enhancing scarring, it 
also was discovered that it also may play a role in alveolar flooding, a pathology of ALI 
(Pittet, et al, 2001).  By inactivating TGF-β, complete attenuation of alveolar flooding 
was achieved in a murine model, which could be insight into possible therapeutic devices 
for ALI (Pittet, et al, 2001). 
 Acute lung injury after hemorrhagic shock (HS) has long been associated with 
TNF-α levels in the lung.  However the exact role the cytokine played was unclear.  To 
establish a clearer view of TNF-α function during ALI after HS, a study was performed 
to determine the relationship between pulmonary TNF-α and neutrophil accumulation 
and lung leak.  Upon induction of HS in mice by removal of 30% of their total blood 
volume, a slight increase was seen in TNF-α (Song, et al, 2001).  However, neutrophil 
accumulation preceded this increase.  Normally, the neutrophil increase would follow an 
increase in TNF-α, as the cytokine is an inducer of neutrophil activity.  A knockout 
mouse was produced that lacked TNF-α.  The neutrophil buildup and lung leak were 
eliminated completely, but restored in a knockout mouse supplied with a recombinant 
TNF-α plasmid (Song, et al, 2001).  The lung leak and neutrophil accumulation were also 
prevented in mice that lacked the p55 TNF-α receptor (Song, et al, 2001).  Even with the 
small amounts of TNF-α restored by plasmids, the neutrophil buildup and lung leak, 
which are key components of ALI, were again detected.  These results show that a low 
level of pulmonary TNF-α is adequate to induce ALI during hemorrhagic shock. 
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SARS and Cytokines 
 Severe acute respiratory syndrome has proven itself a very dangerous viral 
infection.  It can spread very quickly, similar to the flu, through close contact with an 
infected individual.  It also can cause death if not treated promptly and correctly.  The 
containment of the outbreak in late 2002 and early 2003 was crucial in stopping the 
spread of this virus.  Now, we have more time to study this new virus and determine what 
exactly occurs with an infection.  This information has not been clearly established and is 
of much interest to many people around the world. 
 One direction in studying the pathology of SARS is to observe cytokines and 
determine their function during infection.  As has been established in the previous 
sections, cytokines are key mediators in immune responses.  Determining the roles of 
cytokines like TNF-α and TGF-β in a SARS CoV infection could lead to the rational 
development of therapeutic interventions or vaccine strategies.  It has been established 
that during a SARS CoV infection, the levels of TGF-β and TNF-α in the blood do 
fluctuate more than normal (Zhang, et al, 2004).  With that and the previous information 
given, it can be presumed that these cytokines do play large roles in a SARS CoV 
infection.  If we can look at the cytokine patterns and accumulation ex vivo in autopsy 
lung tissue, then experiments can be designed for use in vitro.  Then, if the effects of 
TNF-α and TGF-β can be assessed in vitro, an area of focus could be established for 
experiments in vivo.    
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PROJECT PURPOSE 
 The background information given above now allows a statement of the purpose 
of this project.  The overall goal of biologists studying SARS CoV is to create a vaccine 
or an effective cure that will either eliminate the virus from the human population, or 
make it easier to detect and cure it.   The biggest problem with this goal is that the 
pathogenesis of SARS CoV infection is highly unclear.  We must first investigate the 
SARS CoV infection to find points of interest for vaccines.  In other words, we must start 
at the bottom of the ladder and work upwards.  This MQP project started at the bottom of 
the ladder, and investigated the levels of two cytokines (TNF-α and TGF-β) and their 
location in lung tissue from two fatal cases of SARS.  The project also investigates what 
types of cells the SARS virus is infecting.  Immunofluorescence microscopy was used to 
show where these cytokines are located in relation to SARS CoV infected cells, as well as 
what types of cells the SARS CoV was infecting.  With this information, experiments can 
be created for use in vitro with live virus applications to move further towards a vaccine 
or cure.        
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METHODS 
 
  
Lung Samples 
 The human lung tissue sections used in this project were from two fatal cases of 
SARS from the Philippines.  The sections were cut at 4-5 microns and fixed in formalin 
prior to their use in this study.  They were then embedded in paraffin and mounted on 
slides.   
 
Immunoperoxidase Staining 
 To visualize which cells contain TGF-β and TNF-α in the fixed tissue, 
immunoperoxidase staining was used.  The general procedure from the Vectastain ABC 
kit for immunohistochemical staining was followed.  The slides were deparaffinized in 
xylene and rehydrated in a graded alcohol series.  The slides were then immersed in 0.01 
M citrate buffer solution and heated for 10 minutes as an antigen retrieval step.  The 
primary antibody used was a mouse derived anti-human TGF-β from Serotec.  The 
control primary antibody used was a mouse purified IgG isotype control.  The anti-
cytokine and isotype control were diluted in phosphate buffered saline (PBS), to a final 
concentration of 0.33 µg/mL.  Slides were incubated for 2 hours in primary antibody, 
followed by a 30-minute incubation in a biotinylated secondary antibody supplied in the 
ABC kit.  To visualize, a diaminobenzidine (DAB) solution was used, and slides were 
incubated for 7 minutes with the DAB.  The slides were then counterstained with 
hemotoxylin.  A graded alcohol series was used to dehydrate the slides, and then a xylene 
based mounted media was used to mount for viewing.   
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Single Color Immunofluorescence Staining 
 The procedure for immunofluorescence staining was derived from several 
sources, including personal communication with researchers who have performed the 
procedure before.  As in immunoperoxidase staining, the slides were deparaffinized, 
rehydrated and treated with the citrate buffer solution to bring antigens to the surface of 
the cells.  The slides were the incubated for 20 minutes in diluted normal serum, derived 
from a goat, the same species from which the secondary antibody was derived.  The 
purpose of this step is to prevent any non-specific staining.  The slides were then 
incubated for 2 hours in primary antibody.  This was followed by a 30-minute incubation 
in a secondary antibody which was conjugated to a fluorophore.  Several washes in PBS 
were performed between each step in the procedure to wash away previous solutions.  
The slides were then mounted with an aqueous mounting media for viewing.   
 
Autofluorescence Control 
 To solve autofluorescence in the tissue at emissions around 488 nanometers, a 30 
minute incubation in 0.25 % Sudan Black B solution was used.  This step was inserted in 
the general procedure for immunofluorescence staining immediately before the mounting 
step.  This incubation significantly reduced autofluorescence in the tissue when observed 
at 488 nanometers (Baschong et al, 2001).   
 
 26
Antibodies and Dilutions 
 When staining for the S-protein of the SARS coronavirus, an antibody raised in 
rabbit was used and normal rabbit serum was used as an isotype control, both obtained 
from a local lab at UMass Medical School.  Both antibodies were used at a 1:500 
dilution.  To detect TNF-α, a goat IgG biotinylated anti-TNF-α was obtained from R+D 
Systems.  This antibody was used at a concentration of 7.5 micrograms/mL.  The anti-
TGF-β antibody was raised in mouse and obtained from Serotec.  This antibody was used 
at a concentration of 0.33 micrograms/mL.  All cell surface marker antibodies (CD68, 
EMA) were raised in mouse and obtained from Dako.  The antibodies against CD68 and 
EMA were used at a 1:25 dilution   
 Secondary antibodies conjugated to different flourophores were obtained from 
Molecular Probes Inc., all of the AlexaFluor variety.  AlexaFluor goat anti-rabbit 488 
(green) was used to visualize the S-protein.  AlexaFluor streptavidin 647 (deep red) was 
used to view the biotinylated TNF-α and TGF-β.  All secondary fluorophore antibodies 
were used at a dilution of 1:250, which was obtained through performing a dilution series 
of the secondary antibody and determining the lowest dilution that gave no background 
staining. 
 
Two Color Immunofluorescence Staining 
 When two color immunofluorescence staining was performed, the same protocol 
as single color staining was followed with one slight alteration.  During the primary and 
secondary antibody incubations, the antibodies for all three desired antigens, S-protein, 
cytokine and cell surface marker, were mixed together in the same solution.  Since all 
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antibodies were raised in different species, there was no foreseen interaction in the 
incubating solution.   
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RESULTS 
  
 The first step in determining the relationship between SARS CoV infected cells 
and the cytokines in question was to prove that these cytokines exist in the infected 
tissue.  Once that fact was established, immunofluorescence staining was used to show 
the location of SARS CoV infected cells in relation to the cytokines.  Lastly, the tissue 
was stained for cell surface markers to add a third aspect of location.   
 To determine the existence of TGF-β and TNF-α in the infected tissue, simple 
immunohistochemical staining was used.  First, negative control slides were run using a 
purified mouse IgG isotype control antibody (Figure 5 A-D).  As expected, the resulting 
slides showed no positive staining, with all tissue and cells staining blue.      
 
Figure 5 – Negative Controls for TGF-β and TNF-α – Panels A and B are the controls for 
Case A TGF-β and TNF-α, respectively, at 400x magnification.  Panels C and D are the controls 
for Case B TGF-β and TNF-α, respectively.  Panel C is at 100x magnification and Panel D is 
400x magnification.  There is no positive brown stain in any of the tissue or cells. 
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The tissues were then labeled with anti-human TGF-β and TNF-α antibodies and 
visualized using peroxidase staining and DAB (Figure 6).  The resulting positive stain is 
brown against the counterstain color of blue.  For both cytokines, there was definitive 
positive staining in the tissue and some isolated cells (Figure 6).  It is clear which cells 
have stained brown, as the blue counterstain can be seen in some tissue and cells which 
are negative for cytokine. 
 
Figure 6 – Positive Stain for TGF-β and TNF-α – Panels A and B are Case A tissue stained for TGF-β 
and TNF-α, respectively.  Panels C and D are Case B stained for TGF-β and TNF-α, respectively.  All 
panels are 400x magnification.  The brown stain can be seen in all samples, showing that the cytokines are 
present in the infected tissue. 
 
 
TGF-β staining (left panels) will stain TGF-β positive cells, as well as blood 
platlets and red blood cells.  Some of the positive staining observed in Figure 6 is this 
blood factor staining, but definitive large cells, most likely macrophages, are staining 
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positive as well as positive stain in the interstitium.  The staining for TNF-α (right panels) 
also shows distinct, round cells staining positive as well as TNF-α in the tissue. 
 The tissue was ready to be analyzed with immunofluorescence microscopy using 
one, two and three colors.  First, an anti-human antibody against the SARS CoV S-
protein, raised in rabbit, was obtained and the tissue was stained (Figure 7).      
 
   
To visualize the S-protein, an anti-rabbit secondary antibody that was conjugated to a 
fluorescent dye was used.  The Alexa 488 dye was similar to fluorescein isothiocyanate 
(FITC) and exhibited a bright green color (panels B and C) under the correct filter of 
fluorescent light.  Therefore, the positive cells would light up green under the 
microscope.  There was a problem with autofluorescence of the lung tissue itself.  An 
incubation in Sudan Black B dye was used to lessen the autofluorescence, but the tissue 
Figure 7 – IF staining for SARS-CoV S-
Protein – Panels B and C show Case A and 
B, respectively, stained for the S-protein of 
the SARS virus.  Panel A is a negative 
control.  The positive cells can be seen as 
lighting up bright green, as compared to the 
control.  All pictures were taken at 200x 
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still stained green.  The positive cells, however, glowed a much brighter and more intense 
green; so distinguishing positive from negative was relatively easy.  It was seen that in 
both Case A and Case B tissue, there was positive S-protein staining (Figure 7).  Case A 
tissue was well intact structurally (Figure 7 Panel B), but Case B showed a deteriorated 
lung structure, so some of the pictures are less clear (Figure 7 Panel C).  This case was 
much more hemorrhagic in nature and caused more lung damage than Case A.  
 The next step in the process was a double stain for the SARS CoV S-protein and 
the cytokines.  This localizes the cells positive for SARS CoV and the cells that were 
producing cytokines.  First a stain was performed using the S-protein antibody and a 
mouse anti-human TGF-β antibody.  The S-protein was labeled with green again (Figure 
8, B and D). and the TGF-β was labeled with Alexa 647, a deep red color (Figure 8, A 
and C).  The TGF-β isotype mouse control (Figure 8 A and B) showed no staining.  
When stained alone, the TGF-β produced an expected signal (panel C).  The same frame 
for the single TGF-β stain was also used for the S-protein picture.  These two pictures 
were then digitally combined to give a two-color picture showing both objects of interest 
(Figure 8 D).  Using both pictures, it can be seen that most of the SARS CoV infected 
cells do not show positive for TGF-β.   
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Figure 8 – IF double color stain for S-protein and TGF-β on Case A – Panels A and B are the negative 
controls for both mouse (red, TGF-β) and rabbit (green, viral S-protein).  Panel C shows TGF-β stain only.  
Panel D is the double color showing both S-protein and TGF-β.  The arrows indicate a special subset of 
viral infected cells that express TGF-β. 
 
 
The pictures for TNF-α (Figure 9) show similar results.  The TNF-α was stained 
using a mouse anti-human TNF-α antibody.  This was then visualized using AlexaFluor 
555 secondary antibody.  The negative control for TNF-α (Figure 9 A) showed no 
staining as expected.  The TNF-α stain alone (Figure 9 B) showed positive stain in the 
tissue as well as some cells, as expected based on the IHC results.  The S-protein staining 
showed definitive positive cells, as in previous results (Figure 9 C).  The double color 
stain (panel D) showed that most SARS CoV infected cells did not have positive stain for 
TNF-α.  The white arrows (Panels B and C) show cells that stain positive for TNF-α but 
 33
not for S-protein.  The yellow arrows in the same panels indicate cells positive for S-
protein, but not TNF-α. 
 
 
Figure 9 – IF double color stain for S-protein and TNF-α on Case B – Panel A is the negative control 
for goat IgG (red, TNF-α).  The isotype control for rabbit IgG also showed very little background (data not 
shown).  Panel is a TNF-α stain only.  Panel C is a stain for S-protein only.  Panel D is the double color 
stain for TNF-α and the S-protein.  The white arrow indicates cells positive for TNF-α and negative for S-
protein.  The yellow arrow indicates a large cell positive for S-protein, but not TNF-α. 
 
 To more clearly illustrate where the S-protein is being detected, an antibody 
against cell surface markers was used.  The assumption was that the S-protein, and 
therefore SARS CoV, would be most prominent in the macrophages of the lung.  To 
detect macrophages, an antibody against the marker CD68 was used (Figure 10).  A 
mouse control antibody yielded no positive staining (Figure 10 A).  There was a certain 
amount of background fluorescence, but the positive stain could be clearly distinguished.  
The rabbit control used for the S-protein also showed no positive stain, with a small 
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amount of background fluorescence (data not shown).  First, a picture showing just CD68 
positive cells staining blue was taken.  A few cells were found that were illuminated more 
brightly than background, and upon further investigation, were determined to be 
macrophages (Figure 10 B).  Next, the same frame was used to take a picture showing 
only S-protein positive cells, staining green as before (Figure 10 C).  The two were then 
combined to show both interests in the same frame (Figure 10 D).  By comparing the two 
single color pictures, it is clear that no cells show two colors.  In other words, one color is 
not covering another in the combined color picture.  This pattern held true throughout all 
the slides examined with this stain.  This data shows that the S-protein, therefore SARS 
CoV, is not contained in macrophages.      
   
Figure 10 – Double color stain for S-protein and CD68 on Case B– This figure shows 
staining for the SARS CoV S-protein and the cell surface marker CD68.  Panel A is a 
negative control slide for the mouse isotype antibody.  Panel B shows positive staining for 
the CD68 cell marker, with positive cells staining blue.  Panel C shows staining for the 
SARS CoV S-protein, as has been shown before.  Lastly, Panel D shows both previous 
pictures combined into one, showing both colors in the same frame.  There is no 
overlapping colors, therefore no positively stained macrophages expressing S-protein.  
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 Since the S-protein positive cells were not staining positive for CD68, it was 
theorized that the SARS CoV infected cells were epithelial cells.  To investigate this idea, 
the same procedure was used as for CD68 staining, substituting an antibody against 
epithelial membrane antigen (EMA) for the CD68 antibody (Figure 11).   
 
 
 
Figure 11 – Double stain for S-protein and epithelial membrane antigen on Case B– This 
figure shows the double stain for the SARS CoV S-protein and CD68.  Panel A is the mouse IgG 
isotype control showing no positive staining, with some background fluorescence.  A control for 
rabbit IgG was also run, showing no positive staining and limited background fluorescence (data 
not shown).  Panel B is the stain for EMA alone.  The arrow indicates probable positive staining.  
Panel C is positive S-protein containing cells, as seen previously.  Panel D is the combination of 
Panels B and C, showing both EMA and S-protein locations.   
 
 
The anti-EMA antibody was also a mouse-derived monoclonal antibody.  As before, a 
mouse IgG isotype control was used and the result was no positive staining, although 
some background staining did exist (Figure 11 A).  From there, a picture was taken of 
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EMA staining alone.  There was some probable positive signal, indicated by the arrow in 
the picture (Figure 11 B).  Again, the anti-S-protein antibody was used and a bright, 
positive signal was produced (Figure 11 C).  The two photos were then combined to show 
the two desired aspects in the same frame (Figure 11 D).  It can be seen that no cells that 
stain positive for S-protein also stain positive for EMA, as well as the converse statement 
(Figure 11 B, C, D).  The bright cells that stain positive for S-protein in Panel C do not 
show the faintest signal in the EMA stain, Panel B.  
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DISCUSSION 
 
To begin analyzing the results of this study, it would be beneficial to review them.  
Starting with immunohistochemistry, it was shown that TGF-β and TNF-α were both 
present in SARS CoV infected lung tissue.  Next, immunofluorescence was used to show 
cells positive for the SARS CoV S-protein.  These two factors were then combined into a 
two-color immunofluorescence stain.  It was seen that cells containing SARS CoV S-
protein did not stain positive for either TGF-β or TNF-α in the vast majority of 
circumstances.  Staining for cell surface markers was performed next.  Cells that were 
positive for S-protein did not stain positive for CD68 or EMA, leading to the fact that 
these viral infected cells were neither macrophages, nor epithelial cells.  These results 
were analyzed and several inferences were made. 
 Several facts can be deduced from the results regarding the cytokines in question.  
It appears as if the cells with virus are not producing either of these cytokines.  This could 
be due to several factors.  The virus may be indeed down-regulating the production of 
these cytokines.  The results are consistent with this theory, in that the cells that show 
bright staining for S-protein do not show the faintest hint of positive signal for either of 
the cytokines.  In the case of TGF-β, this may be a reasonable finding.  TGF-β was 
shown to decrease viral replication in TB induced HIV (Goletti, et al, 1997).  The virus 
would be at an advantage by down-regulating TGF-β production.  However, in the case 
of TNF-α, this is a strange finding.  TNF-α was shown to be up regulated in the 
previously mentioned study.  However, that paper was only one study conducted on HIV, 
not SARS CoV.  A simple explanation is that SARS CoV acts differently than HIV in 
cytokine regulation.  This theory of cytokine down-regulation cannot be justified with 
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immunostaining alone, but rather this result could lead to in vitro experiments that could 
further prove the fact.  
 The other results obtained regarding the cell makers and S-protein containing 
cells provide insight into where SARS CoV is infecting.  Original presumptions, drawn 
from immunohistochemistry, were that the SARS CoV was residing in pulmonary 
macrophages and epithelial cells.  Upon staining for CD68, this was shown to be not true.  
The thought then was that these S-positive cells were epithelial cells.  However, when the 
tissue was stained for epithelial membrane antigen, the results showed again that this was 
not true.   There are three main conclusions that can be drawn from this.   The first 
conclusion is that these are true findings.  This would mean that the SARS CoV infected 
cells are neither pulmonary macrophages, nor epithelial cells.  This provides a difficult 
question as to what cells these S-positive cells are.  Macrophages would be the natural 
assumption as to which cells contain the most virus since the main function of 
macrophages is to remove foreign antigens from the body, so naturally they will contain 
viral particles.  Since this fact was shown to be false, epithelial cells would be the next 
guess.  This was also shown to be not true, it is difficult to say what other cells would 
contain this much virus.  This conclusion may be less acceptable due to this fact. 
 The second conclusion is that the CD68 and EMA markers are somehow being 
altered in a fashion that would cause them to be less recognized by the detection 
antibodies.  One theory is that the virus is altering or down-regulating the surface markers 
when it replicates inside the cell.  Another idea is that the cells are dying and their surface 
markers are being altered or down regulated.  This would explain why none of the S-
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protein containing cells are showing positive for CD68 or EMA, when there are definite 
positive cells staining for these two markers elsewhere in the tissue. 
 The third conclusion, which can also be applied to the cytokine antibody tests, is 
that there is some technical aspect that is preventing the two different antigens to be 
shown in the same cell.  The procedure used requires the antibodies to be prepared in the 
same solution when performing the double color stain.  There may be some sort of 
interaction with this method of antibody application.  There may be competition between 
antibodies to bind a certain cell, and the S-protein antibody may have more affinity to the 
cell, preventing any further antibodies from binding.  This would explain the lack of 
overlapping colors in the two color trials.   
 The most useful step in this study would be to attempt a three-color stain, 
consisting of the antibodies for S-protein, one of the cell surface markers and one of the 
cytokines.  This was a goal for this paper and several attempts at it were made.  
Unfortunately, none were successful.  The problem with a three-color stain is to 
effectively coordinate all the antibodies, taking into account their host species.  One 
primary antibody cannot have the same host species as another. If this were to happen, 
the secondary antibody would stain both these antibodies the same color, not giving any 
distinction to the two desired antigens.  This was the largest problem encountered with 
this study.  The use of biotinylated primary antibodies was implemented, but the 
antibodies were not useful for immunohistochemistry on paraffin embedded, formalin 
fixed tissue.  To set up a plan for an effective three-color stain would be the next logical 
step for this study.   
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 The results obtained in this study can be used to formulate studies that can be 
performed in vitro.  A study could be designed to assess the cytokine production of live 
cells infected with SARS CoV.  This could further clarify the finding that the SARS CoV 
infected cells are not producing TNF-α or TGF-β.  Analysis of SARS CoV infected 
macrophages and epithelial cells could provide insight into the finding that the SARS 
CoV infected cells were neither of the two cells expected.   
 The results of this study as of now show some progress on the investigation of the 
pathology of SARS.  More intensive study into antibodies and their target molecules 
could be used to provide further pictures, including the three-color stain that was 
unsuccessful in this project.  This is the direction that needs to be followed to determine a 
detailed description of SARS CoV and its method of infection.     
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